Rodman & Renshaw Begins Coverage on PolyPid (NASDAQ:PYPD)

Rodman & Renshaw began coverage on shares of PolyPid (NASDAQ:PYPDFree Report) in a report released on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $13.00 price objective on the stock.

Other research analysts have also recently issued reports about the stock. HC Wainwright reduced their price target on shares of PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, December 26th. Craig Hallum started coverage on PolyPid in a report on Monday, November 4th. They issued a “buy” rating and a $10.00 price target for the company.

Get Our Latest Stock Report on PYPD

PolyPid Stock Performance

Shares of NASDAQ:PYPD opened at $2.99 on Tuesday. The firm has a market capitalization of $14.34 million, a PE ratio of -0.38 and a beta of 1.32. PolyPid has a 12 month low of $2.37 and a 12 month high of $7.00. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.00 and a quick ratio of 1.00. The business has a 50-day moving average of $3.10 and a two-hundred day moving average of $3.36.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC acquired a new stake in PolyPid Ltd. (NASDAQ:PYPDFree Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned about 2.89% of PolyPid at the end of the most recent reporting period. Institutional investors own 26.47% of the company’s stock.

About PolyPid

(Get Free Report)

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.

Recommended Stories

Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.